Maurice C. M. L. Buzink

This paper identifies abemaciclib, an FDA-approved CDK4/6 inhibitor, as a potent agonist of ACKR3, an atypical chemokine receptor, revealing its ability to modulate chemokine availability and receptor activity.

This study characterizes VUF16840 as a selective inverse agonist of ACKR3 that inhibits constitutive and chemokine-induced signaling by stabilizing the inactive conformation of the receptor.